Added to YB: 2026-07-07
Pitch date: 2026-03-31
ALNY [bullish]
Alnylam Pharmaceuticals, Inc.
-5.91%
current return
Author Info
No bio for this author
Company Info
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Market Cap
$41.8B
Pitch Price
$332.69
Price Target
N/A
Dividend
N/A
EV/EBITDA
47.22
P/E
79.18
EV/Sales
9.73
Sector
Biotechnology
Category
growth
Brown Advisory Large-Cap Growth Strategy New Position: Alnylam Pharmaceuticals, Inc.
ALNY (new position): Leading RNAi therapeutics developer targeting serious, underserved diseases. Initiated on share price weakness creating attractive entry. Repeatable ability to develop/commercialize novel therapies. Expanding portfolio provides durable revenue base via patient adoption. Differentiated platform + growing pipeline for long-term growth. Previously owned in Mid-Cap strategy.
Read full article (1 min)